Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and <scp>JAK</scp> inhibitors: A case series-Reference-Cited by-同舟云学术

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series

Published:2024-02-29 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gori Niccolò¹²^ORCID,Ippoliti Elena¹²,Ferrucci Silvia Mariel³,Balato Anna⁴,Ortoncelli Michela⁵,Maurelli Martina⁶^ORCID,Galluzzo Marco⁷⁸^ORCID,Munera Campos Monica⁹^ORCID,Seremet Teofila¹⁰,Di Nardo Lucia¹²^ORCID,Antonelli Flaminia¹²,Coscarella Giulia¹²,Conrad Curdin¹⁰^ORCID,Carrascosa Jose Manuel⁹^ORCID,Bianchi Luca⁷⁸,Argenziano Giuseppe⁴^ORCID,Ribero Simone⁵^ORCID,Girolomoni Giampiero⁶^ORCID,Marzano Angelo Valerio³¹¹^ORCID,Chiricozzi Andrea¹²^ORCID,Peris Ketty¹²^ORCID,

Affiliation:

1. Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale Università Cattolica del Sacro Cuore Rome Italy

2. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

3. Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

4. Unit of Dermatology—University of Campania Luigi Vanvitelli Naples

5. Section of Dermatology, Department of Medical Sciences University of Turin Turin Italy

6. Section of Dermatology and Venereology, Department of Medicine University of Verona Verona Italy

7. Department of Systems Medicine University of Rome "Tor Vergata" Rome Italy

8. Dermatology Unit Fondazione Policlinico “Tor Vergata” Rome Italy

9. Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP) Autonomous University of Barcelona (UAB) Badalona Spain

10. Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland

11. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.19929

Reference6 articles.

1. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

2. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

3. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

4. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: A multicentre real‐world study

5. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study